Table 1. Characteristics and outcome of... | American Society of Hematology

Table 1.

Characteristics and outcome of evaluable patients

ID	Age/sex	Diagnosis; DS at time of mLST infusion	Prior treatments	Conditioning regimen; GVHD prophylaxis	HSCT donor	GVHD after HSCT, status before mLSTs	DL	Immune suppression at time of mLST	Day of mLSTs after HSCT	GVHD after mLST infusion	Post-mLST infusion relapse	Post-mLST infusion survival
2	41/M	Ph-like, poor risk cytogenetics; CR1*	Hyper-CVAD+ofatumumab ×5 cycles	TBI (12Gy)/CTX; tacro/MTX	MSD	None	1	Tacro	66	None	No	Alive at 47 mo
3	17/F	Relapsed ALL; CR2, MRD^neg	Completed therapy for HR- ALL per COG AALL1131→relapse→ reinduction per COG AALL1331HSCT	TBI (6Gy)/flu/ alemtuzumab; tacro	MSD	Acute GVHD grade 2; resolved	1	Tacro	107	None	Yes 6 mo	Died at 18 mo (relapse)
4	14/M	Ph⁺ALL; CR2, MRD^neg	Completed therapy for HR- ALL COG AALL1122 (dasatinib)→relapse → reinduction on COG AALL0434 (dasatinib)→HSCT	TBI (12Gy)/CTX; ara-C; tacro methylpred	MSD	Acute GVHD grade 2; resolved	1	Tacro	127	Chronic moderate GVHD 5 mo after infusion	No	Died at 9.5 mo (Varicella zoster infection)
5	20/F	Ph⁺ALL; CR3, MRD^neg	Induction and consolidation-COG AALL0622 (dasatinib)→MSDSCT→ relapse→ALLR3 reinduction chemotherapy→CD34⁺ top-off†	TBI (6Gy)/flu/ alemtuzumab; tacro	MSD	None	1	None‡	48	None	No	Alive at 51 mo
7	12/F	T-cell ALL; CR2, MRD^neg	Completed therapy for T- ALL COG AALL0434→relapse→ reinduction on COG AALL1231 (bortezomib)→HSCT	TBI (12Gy)/CTX; tacro/MTX	MSD	None	2	None	117	None	No	Alive at 48 mo
8	18/M	HR-ALL; CR1, MRD^neg	Induction and consolidation COG AALL1131→primary induction failure→HSCT	TBI (12Gy)/CTX/ara-C; tacro/MTX	MSD	None	2	Tacro	48	None	No	Alive at 46 mo
10	12/F	T-cell/ MPAL, FLT3⁺; CR1, MRD^neg	Induction and consolidation chemotherapy COG AALL1231→HSCT as high risk	TBI (12Gy)/CTX; tacro/MTX	MSD	Acute GVHD Grade 2; resolved	3	Tacro, pred§	146	None	No	Alive at 36 mo
12	23/F	Ph+ALL, high-risk cytogenetics; CR3; MRD^neg	Completed therapy for COG AALL08P1 (augmented BFM regimen)→relapse 8 y later→hyper-CVAD × 4 cycles→residual disease→CVAD⁺ inotuzumab mo 4 cycles+5 cycles of POMP→HSCT	TBI (2Gy) flu/mel; post-HSCT CTX tacro/MMF	Haplo	None	3	Tacro	111	None	Yes 10 mo	Alive at 24 mo

ID	Age/sex	Diagnosis; DS at time of mLST infusion	Prior treatments	Conditioning regimen; GVHD prophylaxis	HSCT donor	GVHD after HSCT, status before mLSTs	DL	Immune suppression at time of mLST	Day of mLSTs after HSCT	GVHD after mLST infusion	Post-mLST infusion relapse	Post-mLST infusion survival
2	41/M	Ph-like, poor risk cytogenetics; CR1*	Hyper-CVAD+ofatumumab ×5 cycles	TBI (12Gy)/CTX; tacro/MTX	MSD	None	1	Tacro	66	None	No	Alive at 47 mo
3	17/F	Relapsed ALL; CR2, MRD^neg	Completed therapy for HR- ALL per COG AALL1131→relapse→ reinduction per COG AALL1331HSCT	TBI (6Gy)/flu/ alemtuzumab; tacro	MSD	Acute GVHD grade 2; resolved	1	Tacro	107	None	Yes 6 mo	Died at 18 mo (relapse)
4	14/M	Ph⁺ALL; CR2, MRD^neg	Completed therapy for HR- ALL COG AALL1122 (dasatinib)→relapse → reinduction on COG AALL0434 (dasatinib)→HSCT	TBI (12Gy)/CTX; ara-C; tacro methylpred	MSD	Acute GVHD grade 2; resolved	1	Tacro	127	Chronic moderate GVHD 5 mo after infusion	No	Died at 9.5 mo (Varicella zoster infection)
5	20/F	Ph⁺ALL; CR3, MRD^neg	Induction and consolidation-COG AALL0622 (dasatinib)→MSDSCT→ relapse→ALLR3 reinduction chemotherapy→CD34⁺ top-off†	TBI (6Gy)/flu/ alemtuzumab; tacro	MSD	None	1	None‡	48	None	No	Alive at 51 mo
7	12/F	T-cell ALL; CR2, MRD^neg	Completed therapy for T- ALL COG AALL0434→relapse→ reinduction on COG AALL1231 (bortezomib)→HSCT	TBI (12Gy)/CTX; tacro/MTX	MSD	None	2	None	117	None	No	Alive at 48 mo
8	18/M	HR-ALL; CR1, MRD^neg	Induction and consolidation COG AALL1131→primary induction failure→HSCT	TBI (12Gy)/CTX/ara-C; tacro/MTX	MSD	None	2	Tacro	48	None	No	Alive at 46 mo
10	12/F	T-cell/ MPAL, FLT3⁺; CR1, MRD^neg	Induction and consolidation chemotherapy COG AALL1231→HSCT as high risk	TBI (12Gy)/CTX; tacro/MTX	MSD	Acute GVHD Grade 2; resolved	3	Tacro, pred§	146	None	No	Alive at 36 mo
12	23/F	Ph+ALL, high-risk cytogenetics; CR3; MRD^neg	Completed therapy for COG AALL08P1 (augmented BFM regimen)→relapse 8 y later→hyper-CVAD × 4 cycles→residual disease→CVAD⁺ inotuzumab mo 4 cycles+5 cycles of POMP→HSCT	TBI (2Gy) flu/mel; post-HSCT CTX tacro/MMF	Haplo	None	3	Tacro	111	None	Yes 10 mo	Alive at 24 mo

ara-C, cytarabine; COG, Children’s Oncology Group; CTX, cytoxan; DL, dose level; DS, disease status; Flu, fludarabine; GVHD, graft-versus-host disease; Haplo, haploidentical donor; HSCT, hematopoietic stem cell transplant; hyper-CVAD, cyclophosphamide, vincristine, doxorubicin, and dexamethasone; Mel, melphalan; mLST, multiple leukemia-associated antigen specific T cells; MMF, mycophenolate mofetil; MPAL, mixed phenotype acute leukemia; MRD^neg, minimal residual disease negative; MSD, matched sibling donor; MTX, methotrexate; Ph⁺ ALL, Philadelphia positive acute lymphoblastic leukemia; Ph-like, Philadelphia-like; POMP, 6-mercaptopurine+vincristine+methotrexate+prednisone; Pred, prednisone; Tacro, tacrolimus; TBI, total body irradiation.

MRD not available, normal cytogenetics.

†

Received mLST infusion following CD34⁺ stem cell top-off.

‡

Received tyrosine kinase inhibitor (bosutinib, 3 wk post-mLST infusion for 1 y).

Dose: 0.1 mg/kg.

View Large

This Feature Is Available To Subscribers Only